找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Complement Therapeutics; John D. Lambris,V. Michael Holers,Daniel Ricklin Book 2013 Springer Science+Business Media New York 2013 infectio

[復(fù)制鏈接]
樓主: 到來
21#
發(fā)表于 2025-3-25 04:54:59 | 只看該作者
22#
發(fā)表于 2025-3-25 10:01:09 | 只看該作者
23#
發(fā)表于 2025-3-25 12:52:26 | 只看該作者
Targeting gC1qR Domains for Therapy Against Infection and Inflammation,prevent the generation of BK but also reduce C1q-induced or microbial-ligand-induced inflammatory responses. Employing synthetic peptides and gC1qR deletion mutants, we confirmed previously predicted sites for C1q (residues 75–96) and HK (residues 204–218) and identified additional sites for both C1
24#
發(fā)表于 2025-3-25 17:33:33 | 只看該作者
25#
發(fā)表于 2025-3-25 21:19:07 | 只看該作者
The Effects of Selective Complement and CD14 Inhibition on the ,-Induced Tissue Factor mRNA Upregulo effect. Monocyte TF expression and TF activity in plasma microparticles were significantly reduced by C5aRa. Anti-CD14 alone only slightly reduced .-induced monocyte TF expression but showed a modest additive effect when combined with the complement inhibitors. Inhibiting complement and CD14 effic
26#
發(fā)表于 2025-3-26 00:51:27 | 只看該作者
CR2-Mediated Targeting of Complement Inhibitors: Bench-to-Bedside Using a Novel Strategy for Site-Snd (3) avoiding infectious complications or impairment of other important physiological functions of complement when using systemically active complement-blocking agents. This chapter will review data that address these challenges to therapeutic development, with a focus on the development of a nove
27#
發(fā)表于 2025-3-26 04:44:02 | 只看該作者
28#
發(fā)表于 2025-3-26 09:07:31 | 只看該作者
C3 Glomerulonephritis/CFHR5 Nephropathy Is an Endemic Disease in Cyprus: Clinical and Molecular Fin the alterative pathway of complement system, which constitutes a significant part of innate immunity in humans. Histologically, the hallmark observation is the isolated glomerular deposition of C3 complement in the absence of immune complexes. It is considered one of the C3 glomerulopathies, and it
29#
發(fā)表于 2025-3-26 13:30:56 | 只看該作者
30#
發(fā)表于 2025-3-26 18:19:38 | 只看該作者
Innate Immunity as Orchestrator of Bone Marrow Homing for Hematopoietic Stem/Progenitor Cells,onsiveness of transplanted HSPCs to stroma-derived factor-1 (SDF-1) gradient. Furthermore, damaged BM cells release several other chemoattractants for HSPCs such as bioactive lipids sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P) and chemotactic purines (ATP and UTP). In this chapter, w
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-14 09:09
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
柳江县| 固阳县| 黄浦区| 岱山县| 韶山市| 井研县| 琼结县| 名山县| 澜沧| 商南县| 山西省| 万荣县| 酉阳| 白朗县| 都安| 游戏| 静宁县| 纳雍县| 林周县| 曲水县| 大庆市| 城固县| 长沙市| 兰西县| 历史| 韶山市| 天峻县| 六盘水市| 聂拉木县| 民勤县| 湘潭市| 克拉玛依市| 志丹县| 社旗县| 浑源县| 平谷区| 五台县| 淮滨县| 汤原县| 上林县| 兴安县|